Novartis files potential blockbuster eye drug with FDANovartis has filed its ophthalmology drug brolucizumab with the US regulator, a potentially strong competitor in the tough Share XNovartis files potential blockbuster eye drug with FDAhttps://pharmaphorum.com/news/novartis-files-potential-blockbuster-eye-drug/
Fusion raises $105m for radiopharmaceutical trialsRadiopharmaceuticals are already well established in imaging technology for a range of diseases – but their use to Share XFusion raises $105m for radiopharmaceutical trialshttps://pharmaphorum.com/news/fusion-raises-105m-towards-radiopharmaceutical-trials/
Bayer and J&J settle Xarelto lawsuits in USBayer and Johnson & Johnson have agreed to settle more than 25,000 US lawsuits worth more than $775 Share XBayer and J&J settle Xarelto lawsuits in UShttps://pharmaphorum.com/news/bayer-and-jj-settle-xarelto-lawsuits-in-us/
Bayer files prostate cancer drug darolutamide with EU regulatorsAfter filings in the US and Japan, Bayer has submitted data to European regulators for its prostate cancer Share XBayer files prostate cancer drug darolutamide with EU regulatorshttps://pharmaphorum.com/news/bayer-files-prostate-cancer-drug-darolutamide-with-eu-regulators/
Bayer files prostate cancer drug darolutamide in JapanBayer has filed its prostate cancer drug darolutamide with Japanese regulators, in an attempt to ratchet up the Share XBayer files prostate cancer drug darolutamide in Japanhttps://pharmaphorum.com/news/bayer-files-prostate-cancer-drug-darolutamide-in-japan/
Bayer completes US filing for prostate cancer drug darolutamideBayer has completed its rolling marketing application for prostate cancer drug darolutamide in the US, setting up possible Share XBayer completes US filing for prostate cancer drug darolutamidehttps://pharmaphorum.com/news/bayer-completes-us-filing-for-prostate-cancer-drug-darolutamide/
Bayer takes control of Loxo duo as Lilly closes takeoverBayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the Share XBayer takes control of Loxo duo as Lilly closes takeoverhttps://pharmaphorum.com/news/bayer-control-loxo-duo-lilly-takeover/
Bayer/Orion showcase results from prostate cancer challengerBayer and development partner Orion have released detailed results from the trial that will form the backbone of Share XBayer/Orion showcase results from prostate cancer challengerhttps://pharmaphorum.com/news/bayer-orion-showcase-results-from-prostate-cancer-challenger/
FDA breakthrough designation for Bayer and Merck & Co’s AI softwareBayer and Merck & Co have won a breakthrough device designation from the US regulator FDA for artificial Share XFDA breakthrough designation for Bayer and Merck & Co’s AI softwarehttps://pharmaphorum.com/news/fda-breakthrough-designation-bayer-merck-ai/
